Supporting the pandemic response and timely access to COVID-19 vaccines: a case for stronger priority setting and health system governance in Nigeria.
COVID-19
Nigeria
governance
priority-setting
vaccination
Journal
The International journal of pharmacy practice
ISSN: 2042-7174
Titre abrégé: Int J Pharm Pract
Pays: England
ID NLM: 9204243
Informations de publication
Date de publication:
25 Jun 2022
25 Jun 2022
Historique:
received:
26
07
2021
accepted:
21
03
2022
pubmed:
26
4
2022
medline:
29
6
2022
entrez:
25
4
2022
Statut:
ppublish
Résumé
Priority setting and health system governance are critical for optimising healthcare interventions and determining how best to allocate limited resources. The COVID-19 pandemic has buttressed the need for these especially now that vaccines are available to curb the spread of the disease. In many low- and middle-income countries (LMICs), vaccine coverage remains low, due in large part to sub-optimal priority setting and health system governance which has led to inequities in access and has fuelled vaccine hesitancy. An analysis of the situation in Nigeria identified key issues that have affected the health system response to COVID-19 and impeded timely access to the vaccine. These include weak vaccine procurement strategies, limited evidence on strategies for prioritising recipients and approaches for rolling out mass vaccination programmes for the entire population, lack of a communication strategy to reduce the incidence of vaccine hesitancy and failures to proactively address vaccine hesitancy through the implementation of vaccination programmes. Nigeria and other many other LMICs are still facing the prospect of subsequent and potentially worsening waves of the COVID-19 pandemic. Without effective priority setting, there is a risk that the country will not accelerate vaccine rollout quickly enough to achieve high coverage rates that will ensure herd immunity. In the context of existing weaknesses in health system governance, there is an urgent need to strengthen priority settings in Nigeria and identify and implement context-specific solutions that can improve vaccine coverage for the population.
Identifiants
pubmed: 35468198
pii: 6573977
doi: 10.1093/ijpp/riac028
pmc: PMC9129110
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
284-287Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Royal Pharmaceutical Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Milbank Q. 2018 Sep;96(3):568-592
pubmed: 30203603
Trop Med Health. 2014 Jun;42(2):67-75
pubmed: 25237283
Cost Eff Resour Alloc. 2004 Apr 22;2(1):3
pubmed: 15104792
J Glob Health. 2018 Dec;8(2):020601
pubmed: 30023054
Hum Resour Health. 2017 May 12;15(1):32
pubmed: 28494782
PLoS One. 2014 Oct 02;9(9):e108787
pubmed: 25275315
Int J Health Plann Manage. 2022 Mar;37(2):930-943
pubmed: 34763368